BioSpace News Archive

Fact.MR – A Market Research and Competitive Intelligence Provider: According to a Fact.MR study, the global influenza diagnostics market is expected to reach US$ 2.5 billion in 2020, growing at a CAGR of 4% between 2016 and 2020.

The significant rise in the prevalent of chronic diseases across the world, including the increasing incidence of cardiovascular diseases, which need early detection, is influencing the global market for venipuncture procedure analysis significantly.

Femasys Inc., a biomedical company aiming to meet women’s needs worldwide by developing a suite of product candidates that include minimally invasive, in-office technologies for reproductive health, announced the appointment of a new board member, Wendy Perrow.

Cue Biopharma, Inc. announced today it will host a conference call and webcast to provide a clinical update on Wednesday, January 26, 2022 at 4:30 p.m. EST.

NGM Biopharmaceuticals, Inc. announced that David J. Woodhouse, Ph.D., Chief Executive Officer, will present an overview of the company and provide a business update at the following upcoming virtual investor conferences.

BioVie Inc. today announced the treatment of the first patient in the Company’s Phase 2 clinical trial assessing the potential pro-motoric impact of its NE3107 asset in Parkinson’s disease patients.

Pfizer Japan Inc. and OPKO Health, Inc. (NASDAQ: OPK) announced today that the next generation long-acting growth hormone injection, NGENLA® (somatrogon) Inj. 24 mg Pens and 60 mg Pens, has been approved by the Ministry of Health, Labour and Welfare (MHLW) in Japan.

Curis, Inc., a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, announced that James Dentzer, President and Chief Executive Officer, will participate in the following upcoming conferences:

VolitionRx Limited (NYSE AMERICAN: VNRX) (“Volition”), has announced the results of two large scale clinical studies, which show that the company’s Nu.Q® assays, when used in conjunction with the Fecal Immunochemical Test (FIT), can detect colorectal cancer and all high-risk advanced adenomas in symptomatic patients, and thereby reduce unnecessary colonoscopies.

Simulations Plus, Inc. (Nasdaq: SLP), today announced a new funded collaboration with a large pharmaceutical company to modify the GastroPlus® Advanced Compartmental Absorption and Transit (ACAT™) model in support of ongoing research programs for the treatment of gastrointestinal diseases.